| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4f1abd19de3c73406584e46d17cf5694 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-325
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-58 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate |
2017-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c416d1b6f950233030337726bd7dabf |
| publicationDate |
2017-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017326204-A1 |
| titleOfInvention |
Compositions and methods for treating heart failure |
| abstract |
The present invention provides methods for treating chronic heart failure patients using the medication comprising neureplin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the result of the test is within a favorite treatment zone, the patient is suitable for heart failure treatment by administering an effective amount of neuregulin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10702585-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10894815-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10561709-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253573-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10441633-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11179323-B2 |
| priorityDate |
2011-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |